ZENITHDRUG — Zenith Drugs Share Price
- IN₹1.34bn
- IN₹1.60bn
- IN₹1.15bn
- 11
- 35
- 43
- 16
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.74 | ||
Price to Tang. Book | 4.74 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.94 | ||
EV to EBITDA | 13.76 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 25.84% | ||
Return on Equity | 29.67% | ||
Operating Margin | 7.31% |
Financial Summary
Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | n/a | n/a | n/a | 916.55 | 1,145.19 | n/a | n/a | 24.95% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | +64.7 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Zenith Drugs Ltd is an India-based pharmaceutical manufacturing and trading company. The Company manufactures and trades pharmaceuticals, drugs enzymes and sanitary napkins and all classes of chemicals used for manufacture of the aforesaid and all other kinds of chemicals and their by-products intermediates, derivatives, formulations, and compounds. It offers a range of formulations in various forms, such as ORS powder, liquid orals, ointments, liquid externals, and capsules. Its liquid orals products include Iron & Folic Acid Syrup IP, Hungrykop Syrup, BIozen Multivitamin Syrup, Rexkop DX Syrup, and Zoomol Plus Syrup. Its ointment products include Clobetol GM Cream, Painfree Gel, POVIZ M Ointment, and Candizen Cream. Its liquid external section products include Poviz Solutin (Lotion), Bioscaby Lotion, Permethirn Lotion, Gamma Benzene Hexachloride 1% Lotion, and Scabikop Lotion. Its capsule section products include Pyvoxee Spas Plus Capsule, BIO-Omi Capsule, and Lopagen Capsule.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- November 15th, 2000
- Public Since
- February 27th, 2024
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 17,148,800
- Address
- Depalpur, INDORE, 453001
- Web
- http://www.zenithdrugs.com/
- Phone
- Auditors
- M/S. Badaya & Co
Similar to ZENITHDRUG
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 18:18 UTC, shares in Zenith Drugs are trading at IN₹62.65. This share price information is delayed by 15 minutes.
Shares in Zenith Drugs last closed at IN₹62.65 and the price had moved by over the past 365 days. In terms of relative price strength the Zenith Drugs share price has matched the S&P BSE 100 Index by over the past year.
There is no consensus recommendation for this security.
Zenith Drugs does not currently pay a dividend.
Zenith Drugs does not currently pay a dividend.
Zenith Drugs does not currently pay a dividend.
To buy shares in Zenith Drugs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹62.65, shares in Zenith Drugs had a market capitalisation of IN₹1.07bn.
Here are the trading details for Zenith Drugs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ZENITHDRUG
Based on an overall assessment of its quality, value and momentum Zenith Drugs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zenith Drugs. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹62.65, shares in Zenith Drugs were trading -9.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zenith Drugs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹62.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Zenith Drugs' directors